New obesity drug XW003 takes on semaglutide in Head-to-Head trial
NCT ID NCT07073417
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug called XW003 works better than the existing drug semaglutide for weight loss in Chinese adults with obesity. About 163 participants with a BMI of 30 or higher will receive either drug, and researchers will measure changes in body weight, waist size, and safety. The goal is to find a more effective treatment for managing obesity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test